These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17549477)

  • 1. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
    Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
    Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
    J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
    Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
    J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.
    Wang SW; Kulkarni KH; Tang L; Wang JR; Yin T; Daidoji T; Yokota H; Hu M
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1023-31. PubMed ID: 19264971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia.
    Kotal P; Van der Veere CN; Sinaasappel M; Elferink RO; Vítek L; Brodanová M; Jansen PL; Fevery J
    Pediatr Res; 1997 Aug; 42(2):195-200. PubMed ID: 9262222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of Gunn rats with autologous fibroblasts expressing bilirubin UDP-glucuronosyltransferase: correction of genetic deficiency and tumor formation.
    Seppen J; Tada K; Ottenhoff R; Sengupta K; Chowdhury NR; Chowdhury JR; Bosma PJ; Oude Elferink RP
    Hum Gene Ther; 1997 Jan; 8(1):27-36. PubMed ID: 8989992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gunn rat: a model for inherited deficiency of bilirubin glucuronidation.
    Chowdhury JR; Kondapalli R; Chowdhury NR
    Adv Vet Sci Comp Med; 1993; 37():149-73. PubMed ID: 8273513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
    Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
    Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic conversion of bilirubin monoglucuronide to diglucuronide in uridine diphosphate-glucuronyl transferase-deficient man and rat by bilirubin glucuronoside glucuronosyltransferase.
    Chowdhury JR; Jansen PL; Fischberg EB; Daniller A; Arias IM
    J Clin Invest; 1978 Jul; 62(1):191-6. PubMed ID: 96142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.
    Hidaka M; Yamasaki K; Okumura M; Ogikubo T; Iwakiri T; Setoguchi N; Nishida K; Nagai K; Ikenoue T; Arimori K
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):321-8. PubMed ID: 16770581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete correction of hyperbilirubinemia in the Gunn rat model of Crigler-Najjar syndrome type I following transient in vivo adenovirus-mediated expression of human bilirubin UDP-glucuronosyltransferase.
    Askari FK; Hitomi Y; Mao M; Wilson JM
    Gene Ther; 1996 May; 3(5):381-8. PubMed ID: 9156798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
    J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.